Every AI newsletter, investors ask questions on the investor interaction platform: arabindo, an important overseas strategic partner of rohin, has obtained the license to supply Pfizer nirmatrelvir and developed the drug ritonavir for commercial treatment of covid-19. Does Luo Xin cooperate with him in this field?
Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) ( Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) . SZ) said on the investor interaction platform on May 22 that the company has not yet cooperated with it in this field. The company and Aurobindo Pharma of India jointly established rohin Arvida Pharmaceutical (Chengdu) Co., Ltd. to engage in the R & D, production and sales of products in the respiratory field. Arabindo Pharmaceutical Co., Ltd. is one of the top five pharmaceutical companies in India. Through cooperation with arabindo Pharmaceutical Co., Ltd., the company introduces 13 atomization inhalation products and scarce industry advantageous technology platforms (BFS production lines). The joint venture established by both parties will register such products in China, Europe and the United States through its own or its wholly-owned subsidiaries, and supply the products to the European and American markets. The project helps the company establish a first-line inhalation preparation product line for COPD and asthma, enhance the company’s competitive advantage in China’s respiratory field, and help the company further expand the international market with the help of the global business resources of arabindo Pharmaceutical Co., Ltd. In 2021, rohin Arvida Pharmaceutical (Chengdu) Co., Ltd. obtained the approval certificate of new drug brief application (anda) issued by the U.S. Food and Drug Administration (FDA) for five drugs: levosalbuterol inhalation solution, ipratropium bromide and salbutamol sulfate inhalation solution, ipratropium bromide inhalation solution, salbutamol sulfate inhalation solution and tobramycin inhalation solution.
\u3000
